赛灵斯
摘要
[通用名称] donepezil hydrochloride,盐酸多奈哌齐
［化学名称］ 1-苄基-4-［（5，6-二甲氧基-1-茚满酮-2-基）甲基］哌啶盐酸盐.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2004年第8期755-757,共3页
Chinese Journal of New Drugs
参考文献4
-
1程勇,宋友华,傅得兴.新一代治疗阿尔茨海默病的胆碱酯酶抑制剂多奈哌齐[J].中国新药杂志,2000,9(5):300-303. 被引量：17
-
2[2]Barner EL,Gray SL.Donepezil use in Alzheimer disease[J].Ann Pharmacother,1998,32(1):70-77.
-
3[3]Rogers SL,Farlow MR,Doody RS,et al.A 24-week,double-blind,placebo-controlled trial of donepezil in patients with Alzheimer disease[J].Am Acad Neurol,1998,50(1):136-145.
-
4[4]Rogers SL,Doody RS,Mohs RC,et al.Donepezil improves cognition and global function in Alzheimer's disease:a 15-week,double-blind,placebo-controlled study.Donepezil Study Group[J].Arch Intern Med,1998,158:1021-1031.
二级参考文献14
-
11，Araki S, Yamanishi Y,Kosasa T, et al. E2020, a novel centrally acting acetylcholinesterase inhibitor ⑴:inhibitory action on cholinesterase. Jpn J Pharmacol, 1989, 49 (Suppl)∶S155
-
22，Svensson AL, Nordberg A TI. Tacrine and donepezil attenuate the neurotoxic effect of Abeta (25-35) in rat PC12 cells.Neuroreport, 1998, 9(7)∶1519
-
33，Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HClfollowing single oral doses.Br J Clin Pharmacol, 1998,46(Suppl1)∶S1
-
44，Rogers SL, Cooper NM, Sukovaty R,et al.Pharmacokinetic and pharmacodynamic profile ofdonepezil HCl following multiple oral doses. Br J Clin Pharmacol,1998, 46(Suppl1)∶S7
-
55，Rogers SL, Farlow MR, Doody RS,et al. A 24-week, double-blind, placebo-controlledtrial of donepezil in patients with Alzheimer's disease.Neurol, 1998,50(1)∶136
-
66，Rupniak NM, Tye SJ, Field MJ. Enhanced performance of spatial and visual recognitionmemory task by the selective acetylcholinesterase inhibitor E2020 in rhesusmonkeys.Psychopharmacology, 1997, 131(4)∶406
-
77，Mihara M, Ohnishi A, Tomono Y,et al. Pharmacokinetics of E2020, a new compound forAlzheimer's disease, in healthy male volunteers. Int J Clin Pharm Ther Toxicol, 1993,31(5)∶223
-
88，Ohnishi A, Mihara M, Kamakura H,et al. Comparison of pharmacokinetics of E2020, a newcompound for Alzheimer's disease, in healthy young and elderly subjects. J Clin Pharmacol,1993, 33(11)∶1086
-
99，Tiseo PJ, Rogers SL, Friedhoff LT. Pharmacokinetics and pharmacodynamic profile ofdonepezil HCl following evening administration. Br J Clin Pharmacol, 1998,46(Suppl1)∶S13
-
1010，Tiseo PJ, Perdomo CA, Friedhoff LT. Metabolism and elimination of 14 C-donepezilin healthy volunteers: a single-dose study. Br J Clin Pharmacol, 1998,46(Suppl1)∶S19
共引文献16
-
1吴海燕,周金云.治疗阿尔茨海默病药物的研究进展[J].中国新药杂志,2004,13(7):583-586. 被引量：10
-
2盛荣,胡永洲.多奈哌齐的合成研究[J].中国药学杂志,2005,40(18):1421-1424. 被引量：2
-
3王淑平,史宇翔.治疗阿尔茨海默病的胆碱酯酶抑制剂的研究进展[J].中国药业,2005,14(10):78-79. 被引量：5
-
4胡锦芳,熊玉卿.多奈哌齐抗阿尔茨海默病的药理及临床研究进展[J].药品评价,2008,5(5):233-236. 被引量：11
-
5王晓琴,何明华,赵金武.盐酸多奈哌齐的合成研究[J].化学试剂,2011,33(2):175-176. 被引量：4
-
6陈丹,向瑾,余勤,梁茂植,南峰,秦永平.HPLC-MS/MS法测定人血浆中多奈哌齐及其代谢物6-O-去甲基多奈哌齐浓度[J].中国新药杂志,2012,21(16):1912-1915. 被引量：1
-
7冯建鹏,祝传宝,胡丽娜,王伟.高质量盐酸多奈哌齐的制备方法[J].河北化工,2012,35(9):12-13. 被引量：3
-
8单玲星,高加索,何宇轩,孙平华,陈卫民.盐酸多奈哌齐的合成[J].中国医药工业杂志,2013,44(11):1084-1085. 被引量：3
-
9李玉龙,宋丹,吴涛,毛光银.盐酸多奈哌齐的合成工艺优化[J].江西化工,2013,29(4):199-200.
-
10陈子晟,罗焕敏.阿尔茨海默病的胆碱能药物治疗[J].中国新药杂志,2001,10(6):415-419. 被引量：15
-
1郑澄,林汉森.1-茚满酮的制备及其热稳定性初步研究[J].精细化工中间体,2009,39(1):42-43.
-
2黄胜炎.国外新批准上市的药物新制剂新剂型（85）[J].中国制药信息,2004,20(11):23-24.
-
3朱乐亭,赵志刚.曲莱[J].中国新药杂志,2004,13(8):754-755. 被引量：6
-
4张宜凡.多奈哌齐的合成方法研究[J].安徽医药,2009,13(3):336-337.
-
5杨广声,钱东丽.盐酸齐拉西酮片[J].中国新药杂志,2006,15(23):2081-2082. 被引量：3
-
6王来海,黄素培,潘保中.兰释[J].中国新药杂志,2004,13(7):657-659. 被引量：14
-
7FDA批准Aricept的新指征[J].中国处方药,2006(12):69-69.
-
8钱东丽,杨广声,潘保中.曲宁[J].中国新药杂志,2004,13(7):656-657. 被引量：2
-
9王九文.必存[J].中国新药杂志,2004,13(2):183-184. 被引量：5
-
10刘腾,崔向丽,王春颖.普拉克索的药理和临床研究[J].中国医院用药评价与分析,2009,9(2):157-159. 被引量：5
